Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A Phase Ib/II Study of WNT974 + Encorafenib + Cetuximab in Patients With BRAF V600E-Mutant KRAS Wild-Type Metastatic Colorectal Cancer.

The oncologist - 17 Mar 2023

Tabernero Josep, Van Cutsem Eric, Garralda Elena, Tai David, De Braud Filippo, Geva Ravit, van Bussel Mark T J, Fiorella Dotti Katia, Elez Elena, de Miguel María J, Litwiler Kevin, Murphy Danielle, Edwards Michelle, Morris Van Karlyle

Abstract excerpt

BACKGROUND: WNT974 is a small molecule inhibitor of Wnt signaling that specifically inhibits porcupine O-acyltransferase. This phase Ib dose--escalation study evaluated the maximum tolerated dose of WNT974 in combination with encorafenib and cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer with RNF43 mutations or RSPO fusions. PATIENTS AND METHODS: Patients received once-daily encorafenib...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Cetuximab

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Colorectal Cancer Treatments and Studies

Share to Colorectal Neoplasms

Share to Hypercalcemia

Share to Mutation

Share to Proto-Oncogene Proteins B-raf

Share to Proto-Oncogene Proteins p21(ras)

Source

Open in PubMed Open full text

Identifiers

PMID: 36811382
DOI: 10.1093/oncolo/oyad007
PMCID: PMC10020809

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Phase Ib/II Study of WNT974 + Encorafenib + Cetuximab in Patients With BRAF V600E-Mutant KRAS Wild-Type Metastatic Colorectal Cancer.PMID 36811382Read ↗

Bone Toxicity Case Report Combining Encorafenib, Cetuximab and WNT974 in a Phase I Trial.Semantic proximity Read ↗

Targeting ligand-dependent wnt pathway dysregulation in gastrointestinal cancers through porcupine inhibitionSemantic proximity Read ↗

Pharmacological Inhibition of the Wnt Acyltransferase PORCN Prevents Growth of WNT-Driven Mammary CancerSemantic proximity Read ↗

Recurrent <i>FBXW7</i> mutations bypass Wnt/β-catenin addiction in cancerSemantic proximity Read ↗

Novel drug resistance mechanisms and drug targets in BRAF-mutated peritoneal metastasis from colorectal cancer.Semantic proximity Read ↗

Gastric and rectal administration of encorafenib with targeted chemotherapy against BRAF V600E-mutant rectal cancer with bowel obstruction.Semantic proximity Read ↗

Recurrent mutations in tumor suppressor FBXW7 bypass Wnt/β-catenin addiction in cancer.Semantic proximity Read ↗

Novel PORCN inhibitor WHN-88 targets Wnt/β-catenin pathway and prevents the growth of Wnt-driven cancers.Semantic proximity Read ↗

Targeting Wnts at the source--new mechanisms, new biomarkers, new drugs.Semantic proximity Read ↗

Tazemetostat, an EZH2 inhibitor, in solid tumors harboring SWI/SNF alterations: a phase II basket study.Semantic proximity Read ↗

Structural model of PORCN illuminates disease-associated variants and drug binding sitesSemantic proximity Read ↗

Comprehensive Analysis of R-Spondin Fusions and RNF43 Mutations Implicate Novel Therapeutic Options in Colorectal Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.